acquisition

Amgen BD looking to salvage the revenue being lost from its EPO business. Both Vifor and Davita (converting fast from Epogen to Mircera) are using Roche product. Its best and the only option is Vafseo, which also has better labeling than GSK oral product, and also touts existing partnership with...

Word on the street is a big pharma company is looking to get into cell and genetic therapy and Vertex has the playbook for it. The overweight stock took a hit this week and Wall Street agrees it is priced too high. The leadership at the company is not stellar and the luck they have had is due...

Where to start, unfair, inconsiderate, etc. Either AZ wants to screw us, Alexion exec don’t care or they are stupid....which is it?

Bristol-Myers Squibb acquires Celgene for $74 billion. Celgene stock surges while BMY plunges. 2019 starts well for Celgene. More M&As are in the pipeline in the biopharma space.

Thoughts on this acquisition? How this company is ran? Future of its reps and managers?

Does anyone know the price that was recently paid for EIT by DePuy/Synthes?

Walgreens to buy pharmacy files from 185 Fred's stores for $165 million. Walgreens will be strengthening their presence in Southeastern US through this deal. https://news.alphastreet.com/walgreens-acquires-freds-inc-pharmacy-165-million/

The US Federal Trade Commission (FTC) has given its nod for the proposed $62 billion acquisition of Shire (SHPG) by Japanese firm Takeda Pharmaceuticals. The merger, the largest ever by a Japanese company, was cleared sans any conditions. Takeda plans to close the acquisition during the first...

On Monday, WSJ reported that Stryker is in talks with Boston Scientific for a potential acquisition. But today, Stryker confirmed that it didn't have any discussion with Boston Scientific. https://news.alphastreet.com/stryker-confirms-that-it-didnt-bid-for-boston-scientific/

Stryker makes a takeover offer for Boston Scientific. Will it succeed? Boston Scientific stock surges to a new 52-week high on the acquisition rumor. https://news.alphastreet.com/boston-scientific-spikes-to-new-52-week-high-on-takeover-rumors/

ARMO Biosciences loss in the fiscal year 2017 has increased compared to the fiscal year 2016. I don't know why Lilly is acquiring this loss making company. Will this acquisition really benefit Lilly? https://news.alphastreet.com/eli-lilly-acquires-armo-biosciences-strengthens-oncology-portfolio/

Perseverance finally paid off. After four snubs, Takeda succeeded in notching the biggest deal ever in the pharma history by purchasing Shire. Takeda is eager to expand its presence in the U.S. and hence is paying a whopping $62 billion to get a hold of Shire’s drug portfolio...

Novartis is wagering high on gene therapy with its proposed acquisit ion of AveXis Inc. valued at $8.7 billion. The high-premium deal is expected to be completed in mid-2018. Source https://news.alphastreet.com/novartis-avexis-a-gene-ius-deal/ "The pharmaceutical sector is witnessing many...

P&G eyes Pfizer’s consumer business https://news.alphastreet.com/pg-eyes-pfizers-consumer-business/

https://news.alphastreet.com/consolidation-of-insurers-and-drugs-firms-is-the-new-fad-in-healthcare/ The emerging trend of consolidation among pharmacies and health insurance companies brings hope to the stakeholders as it could bring a positive change to the industry. Cigna Corp has revealed...

If you ask Sansa Stark from HBO’s Game of Thrones, she’ll tell you the best way to go is to team up with someone strong or risk getting killed. And that’s what happens to most acquisitions in the market nowadays. Over the past three years or so, we have seen a plethora of deal announcements...

It's an M&A Monday for the pharma companies. Two major pharma acquisitions announced today. 1) Celgene acquires Juno for $9 billion http://alph.st/pd7bf702 2) Sanofi acquires Bioverative for $11.6 billion Last week, there was a rumor that Celgene's acquisition of Juno and also news about...

Yesterday, WSJ has stated that Celgene is holding talks to acquire Juno Therapeutics. http://alph.st/pd7bf702 Will this move strengthen Celgene? In 2018, the first acquisition was Impact and now the unconfirmed Juno hunting.

When providing the outlook for 2018, Saunders said that Allergan faces LOE losses in 2018. But still it has got good long-term prospects. Saunders says that current stock price doesn't reflect Allergan's true value. Wall Street gives thumbs up to his speech.

Celgene strengthens its cancer portfolio by acquiring Impact Biomedicines. After stopping the Crohn's disease treatment trials and cutting down the 2020 outlook recently, this deal is a positive news for Celgene. But Sanofi had sold the rights of fedrantinib to Impact in 2016 when the drug was...